Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Melanoma × Irinotecan × Clear all

Phase

Phase 1 4 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 Dermatologic 1

Conditions

Colorectal Neoplasms 38 Pancreatic Neoplasms 16 Colonic Neoplasms 12 Rectal Neoplasms 11 Stomach Neoplasms 9 Neoplasms 9 Neuroblastoma 8 Small Cell Lung Carcinoma 7 Rhabdomyosarcoma 7 Neoplasm Metastasis 7 Glioblastoma 7 Sarcoma, Ewing 6 Gastrointestinal Neoplasms 6 Central Nervous System Neoplasms 6 Carcinoma, Non-Small-Cell Lung 6 Glioma 5 Sarcoma 4 Brain Neoplasms 4 Medulloblastoma 3 Intestinal Neoplasms 3 Gliosarcoma 3 Gastrointestinal Diseases 3 Esophageal Neoplasms 3 Digestive System Neoplasms 3 Digestive System Diseases 3 Astrocytoma 3 Advanced Solid Tumors 3 Recurrence 2 Rectal Diseases 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2

Interventions

pembrolizumab 74 Nivolumab 53 Ipilimumab 42 Cyclophosphamide 31 Interleukin-2 24 aldesleukin 23 Temozolomide 17 fludarabine 15 Biopsy 11 trametinib 10 dabrafenib 10 fludarabine phosphate 9 spartalizumab 8 Paclitaxel 8 Dacarbazine 8 sargramostim 7 cemiplimab 7 binimetinib 7 Cisplatin 7 Bevacizumab 7 poly ICLC 6 lenvatinib 6 epacadostat 6 Radiotherapy 6 Granulocyte-Macrophage Colony-Stimulating Factor 6 montanide ISA 51 5 encorafenib 5 atezolizumab 5 Vemurafenib 5 Specimen Handling 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03009058 2024-11-25

MODULATE

Immodulon Therapeutics Ltd

Phase 1/2 Terminated

2 enrolled 7 charts

DermatologicSarcoma

Melanoma, Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡